Analysis of prognostic factors for patients with stageⅠb non-small cell lung cancer after operation
10.3760/cma.j.issn.0253-3766.2017.04.011
- VernacularTitle: ⅠB期非小细胞肺癌术后预后因素分析
- Author:
Peng SONG
1
;
Ruochuan ZANG
1
;
Moyan ZHANG
1
;
Lei LIU
1
;
Shugeng GAO
1
Author Information
1. Department of Thoracic Surgery, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
- Publication Type:Clinical Trail
- Keywords:
Carcinoma, non-small-cell lung;
Prognosis;
Pulmonary surgical procedures
- From:
Chinese Journal of Oncology
2017;39(4):293-297
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To study the prognostic factors for patients with stage ⅠB non-small cell lung cancer (NSCLC) after radical operation (R0).
Methods:The clinical data of 458 patients who underwent radical resection for NSCLC and were pathologically diagnosed with stage ⅠB lung cancer from January 2009 to December 2010, were reviewed retrospectively. Those cases include 269 male patients and 189 female, aged between 28 and 88, with a median age of 61 years. The Kaplan-Meier method and Log rank test were used for univariate survival analysis and the Cox proportional hazards model for multivariate survival analysis.
Results:Among these 458 cases, 66 patients were dead and the 5-year survival rate was 85.6%.The results of the univariate analysis showed that the age ≥65 years, elevated preoperative CEA, preoperative FEV1%pred<70%, vascular carcinoma embolus, and low tumor differentiation were associated with poor prognosis of patients(P<0.05). The results of the multivariate analysis showed that elevated preoperative CEA, preoperative FEV1%pred<70% and low tumor differentiation were connected with poor prognosis of patients (P<0.05).
Conclusions:Elevated preoperative CEA, preoperative FEV1%pred<70% and low tumor differentiation are independent risk factors which influence prognosis and survival rate of patients with stage ⅠB NSCLC, among which those with poorly differentiated tumor could benefit from postoperative chemotherapy.
